Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The material change disclosed is an increase in the holding of Ordinary Shares by Dr. S Dexter, a Connected Person. This increase resulted from the re-investment of the dividend paid to shareholders on July 10, 2014, and the purchase of shares on July 11, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: July 11, 2014 (purchase) and July 10, 2014 (dividend reinvestment).
- Share Price: 1564.7584 pence per Share.
- Individual Involved: Dr. S Dexter (Connected Person).
- Shares Acquired: 157 Ordinary Shares.
- Notification Date: July 16, 2014.